Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Algernon Pharmaceuticals Inc. (AGN.CN)

Canadian Sec - Canadian Sec Real Time Price. Currency in CAD
2.6000-0.1500 (-5.45%)
At close: 03:28PM EST
Advertisement
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.7500
Open2.6500
Bid2.4600 x 0
Ask2.7000 x 0
Day's Range2.5000 - 2.6500
52 Week Range2.1500 - 11.9000
Volume2,600
Avg. Volume4,369
Market Cap6.202M
Beta (5Y Monthly)0.26
PE Ratio (TTM)N/A
EPS (TTM)-2.9560
Earnings DateApr 27, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A

Subscribe to Yahoo Finance Plus to view Fair Value for AGN.CN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • GlobeNewswire

      Algernon Pharmaceuticals Receives U.S. FDA Orphan Drug Designation for Ifenprodil for the Treatment of Idiopathic Pulmonary Fibrosis

      VANCOUVER, British Columbia, Dec. 05, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that the United States Food and Drug Administration (“U.S. FDA”) has granted Orphan Drug Designation (ODD) to Ifenprodil as a treatment for Idiopathic Pulmonary Fibrosis (IPF). Ifenprodil is the sole active ingredient in NP-120, an NMDA receptor a

    • GlobeNewswire

      Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study

      VANCOUVER, British Columbia, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce that it has commenced screening subjects for its Phase 1 clinical study of an intravenous formulation of AP-188 (“N,N-Dimethyltryptamine” or “DMT”) in the Netherlands. The trial will be conducted at the Centre for Human Drug Research (“CHDR”) in L

    • Newsfile

      Algernon Pharmaceuticals: Advancing DMT into a Phase 1 Clinical Trial, CEO Clips Video

      Vancouver, British Columbia--(Newsfile Corp. - November 8, 2022) - Algernon Pharmaceuticals (CSE: AGN) (OTCQB: AGNPF) – The company is focused on the disease area of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease. Algernon was recently granted permission to conduct a Phase 1 clinical study of DMT for the treatment of stroke.If you cannot view the video above, please visit:https://www.b-tv.com/post/cse-agn-algernon-pharmaceuticals-advancing-dmt-into-a-phas

    Advertisement
    Advertisement